CCM
Catalio Capital Management Portfolio holdings
AUM
$477M
This Quarter Return
+9.82%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$457M
AUM Growth
–
Cap. Flow
+$457M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
57.34%
Holding
33
New
33
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Becton Dickinson
BDX
|
$33.7M |
| 2 |
Ascendis Pharma
ASND
|
$29.7M |
| 3 |
Bristol-Myers Squibb
BMY
|
$28.2M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
$27.6M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$24.8M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Becton Dickinson
BDX
$55.3B
| $33.7M | 7.38% | +148,615 | New | +$33.7M |
|
|
2
Ascendis Pharma
ASND
$11.8B
| $29.7M | 6.49% | +215,587 | New | +$29.7M |
|
|
3
Bristol-Myers Squibb
BMY
$96B
| $28.2M | 6.18% | +499,151 | New | +$28.2M |
|
|
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
| $27.6M | 6.04% | +764,668 | New | +$27.6M |
|
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $24.8M | 5.43% | +284,654 | New | +$24.8M |
|
6
Edwards Lifesciences
EW
$47.8B
| $24.7M | 5.4% | +333,144 | New | +$24.7M |
|
7
BridgeBio Pharma
BBIO
$9.89B
| $24.7M | 5.39% | +898,458 | New | +$24.7M |
|
8
LivaNova
LIVN
$3.08B
| $23.7M | 5.19% | +512,447 | New | +$23.7M |
|
|
SEPN
9
Septerna, Inc. Common Stock
SEPN
$539M
| $23.5M | 5.13% | +1,024,245 | New | +$23.5M |
|
10
Cytokinetics
CYTK
$4.23B
| $21.5M | 4.71% | +457,587 | New | +$21.5M |
|
11
Envista
NVST
$3.52B
| $19.7M | 4.3% | +1,019,529 | New | +$19.7M |
|
12
Veracyte
VCYT
$2.39B
| $19.4M | 4.25% | +490,547 | New | +$19.4M |
|
13
Intuitive Surgical
ISRG
$170B
| $19.3M | 4.21% | +36,910 | New | +$19.3M |
|
14
Exact Sciences
EXAS
$8.98B
| $17.4M | 3.8% | +309,103 | New | +$17.4M |
|
15
Dianthus Therapeutics
DNTH
$759M
| $16.6M | 3.64% | +763,471 | New | +$16.6M |
|
16
uniQure
QURE
$896M
| $15.9M | 3.48% | +901,973 | New | +$15.9M |
|
17
Structure Therapeutics
GPCR
$1.11B
| $15.4M | 3.38% | +569,395 | New | +$15.4M |
|
18
Masimo
MASI
$7.59B
| $14.4M | 3.16% | +87,377 | New | +$14.4M |
|
19
Disc Medicine
IRON
$2.07B
| $11.4M | 2.49% | +179,815 | New | +$11.4M |
|
20
ADMA Biologics
ADMA
$4.12B
| $8.79M | 1.92% | +512,724 | New | +$8.79M |
|
|
NARI
21
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $6.77M | 1.48% | +132,545 | New | +$6.77M |
|
22
Boston Scientific
BSX
$156B
| $6.51M | 1.42% | +72,925 | New | +$6.51M |
|
23
Keros Therapeutics
KROS
$618M
| $6.45M | 1.41% | +407,292 | New | +$6.45M |
|
24
Protara Therapeutics
TARA
$120M
| $5.75M | 1.26% | +1,088,691 | New | +$5.75M |
|
25
Mersana Therapeutics
MRSN
$36.5M
| $2.44M | 0.53% | +1,705,036 | New | +$2.44M |
|